Highly Variable Drug Bioequivalence Could Be Shown Through Reference Scaling, Cmte. Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
Reference scaling may be an interim solution to demonstrating bioequivalence for highly variable drug products; in the future, FDA should create a decision tree that allows the bioequivalence range to adjust with the drug's variability, FDA's Pharmaceutical Science Advisory Committee says.
You may also be interested in...
FDA Seeks Input On GI Drug Bioequivalence Standards From Committee
FDA will also offer a revised bio-inequivalence proposal at an Oct. 20 Pharmaceutical Science Advisory Committee meeting. On Oct. 19, the committee will discuss FDA's Critical Path initiative, risk-based GMP progress and parametric interval testing.
FDA Seeks Input On GI Drug Bioequivalence Standards From Committee
FDA will also offer a revised bio-inequivalence proposal at an Oct. 20 Pharmaceutical Science Advisory Committee meeting. On Oct. 19, the committee will discuss FDA's Critical Path initiative, risk-based GMP progress and parametric interval testing.
Bio-Inequivalence Is Not Simply Failure To Show Bioequivalence, FDA Says
FDA will propose standards for demonstrating bio-inequivalence at the April 14 meeting of the Pharmaceutical Science Advisory Committee. Topical bioequivalence and bioequivalence of highly variable drugs will be discussed as well.